Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

The alfapump DSR® system

Content not available.
Please allow cookies by clicking Accept on the banner

Sequana Medical has leveraged its alfapump® experience and is developing alfapump DSR®, a fully implanted system for DSR® therapy in patients with fluid overload due to heart failure.

alfapump DSR® combines three proven elements:

DSR®
  • Safe & well-tolerated
  • Clinically relevant removal of sodium
  • Minimal patient inter-variability
alfapump®
  • Validated technical performance
  • Extensive clinical experience
  • Deep understanding of implementation
Implanted port
  • Many years of clincial experience

The sodium-free DSR® infusate is administered to the peritoneal cavity via the surgically implanted port, which allows for flexible dosing to remove the desired amount of sodium. The DSR® infusate remains there for a pre-determined period of time before the DSR® infusate and the extracted sodium is pumped to the bladder and eliminated through urination.

RED DESERT – a repeated dose alfapump DSR® study in diuretic-resistant heart failure patients

  • Highly effective replacement of high dose loop diuretics
  • Dramatic and long-term improvement in diuretic response
  • Significant improvement in cardio-renal function

More information can be found in the press release and the Webcast by Sequana Medical management on 11 May 2021.

Results were selected for the Late Breaking Science Results at the Heart Failure 2021 Online Congress

SAHARA DESERT – a repeated dose alfapump DSR® study in diuretic-resistant heart failure patients with persistent congestion

Interim data from six patients indicate that alfapump® therapy can:

  • safely, effectively and rapidly eliminate persistent congestion and restore euvolemia
  • considerably benefit cardio-renal status, and
  • dramatically improve diuretic responsiveness for months post-treatment

More information can be found in the press release and the Webcast by Sequana Medical management on 7 December 2021.

About this research

Clinical research

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES

    We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close